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1. INTRODUCTION 
Ocular tuberculosis is a form of extra pulmonary infection and is 
the most common cause of infectious uveitis in spite of its diverse 
clinical presentation and difficulty in a definite diagnosis masking its 
true prevalence. Even with recent revolutionary advances in the 
diagnostic assays and a better understanding of the pathology, diagnosis 
is mainly presumptive, based on history, clinical examinations, 
adjunctive diagnostic tests and response to anti-tuberculous therapy. 
Although the symptoms and signs are not characteristic of tuberculous 
etiology, the chronicity and recurrent form of the disease due to an 
imbalance between the host immune response and the virulence of the 
microbe provides a suspicion to the disease. 
Ocular tuberculosis is acquired in one of the three forms: 
1) Frequently, a hypersensitive reaction to tubercular proteins 
elicited by the host’s intact immune system. 
2) Secondary infection by hematogenous spread from lungs in 
miliary form and 
3) Very rarely, a primary infection from the adjacent ocular tissue. 
Ocular tuberculosis is more common in clinically healed pulmonary 
tuberculosis or an old extra pulmonary tuberculosis. Therefore, with 
exception of miliary tuberculosis, ocular tuberculosis rarely occurs in 
active disease elsewhere but in healthy, well-nourished and apparently 
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normal individuals with healed lesion in some organs more commonly 
lymphatics than the lungs. 
 
2. HISTORY AND BACKGROUND: 
Our understanding of tubercular uveitis today is mainly because 
of the seminal work done by Julius Von Michel[1] (1843-
1911)[Figure1], a German ophthalmologist who also a diabetic for 
many years died because of tubercular infection. In 1883, a year after 
the discovery of the tubercle bacillus by Robert Koch, Von Michel 
published his classical paper giving a detailed description on the 
multiple forms of clinical presentation, dividing them into miliary and 
granulomatous forms and claiming it to be the commonest cause of 
uveitis. Our subsequent knowledge of the disease is built upon his work. 
 
 
 
 
 
 
 
 
 
Figure 1: Julius Von Michel (1843-1911) a German ophthalmologist 
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In 1711 Maître Jan gave the first clinical description of ocular 
tuberculosis in a soldier whose iris sloughed through cornea and eye 
shrank later. In 1807, a century later Autenrieth described yellow 
excrescences in the choroid which we know today as choroidal tubercle 
in a patient who later died of generalized tuberculosis. In 1867 
Cohnheim showed that choroid tubercles were histologically identical to 
tubercles elsewhere in the body and that they are metastatic and part of 
systemic disease. In 1884, couple of years after Koch’s discovery, Haab 
demonstrated tubercle bacilli in the eye. 
The subject of ocular tuberculosis has faced controversies since 
its description and is far from finished yet. The reason is because of the 
pleomorphic presentation owing to variation in massiveness and 
virulence of infection and degree of host’s immune response. Apart from 
choroidal tubercle which are characteristic, other signs are nondescript 
and shows nothing indicating of its pathology. The consequences are, 
the observer is greeted by his critic with enthusiasm, skepticism or 
violent disagreement based on their clinical bias.  
 
3. EPIDEMIOLOGY: 
 Tuberculosis is the third leading infectious cause of death after 
HIV and malaria. According to WHO estimates[2], worldwide one-third 
of the population are infected with Mycobacterium tuberculosis and 3 
million deaths are reported every year of which 20% from Africa, 38% 
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from S.E Asia, 22% from Western Pacific, 6% from U.S and 4% from 
eastern Mediterranean.In India the incidence of ocular tuberculosis is 
reported as 1.39% in patients with pulmonary and extra-pulmonary 
tuberculosis[3][4]. Immunocompetent individuals with latent tuberculosis 
infection (LTBI) run a 5-10% lifetime risk of developing systemic 
reactivation when their immune system is compromised, majority 
developing TB disease within five years of initial infection. High risk 
groups include immigrants from endemic areas, health care 
professionals, indigent and immunocompromised patients (HIV 
infected, chronic disease, immunomodulator therapy).  
 Pulmonary tuberculosis is present in 80% of patients and 20% 
have extra-pulmonary, half of these patients have normal chest 
radiograph and up to 20% are negative for tuberculin skin test. Only 
10% of infected patients develop symptomatic disease and half of these 
develop disease within the first 5 years and the majority are 
asymptomatic.  
 The classical clinical presentations are fever, weight loss and 
night sweats and these symptoms are seen both in pulmonary and extra-
pulmonary tuberculosis. Hence while reviewing the system while 
suspecting tuberculous uveitis one has to keep in mind to elicit the 
relevant history. 
 
 
5 
 
Currently there are three major concerns: 
 First, tuberculosis is the most common opportunistic infection in 
HIV-infected patients mainly in the developing countries. In 2013, of 
the 9 million who were diagnosed with tuberculosis, 1.1 million (13%) 
were HIV positive. Of the 1.5 million individuals who died of 
tuberculosis, 360,000 had concomitant HIV infection[2]. 
Second, is the global threat in the emergence and spread of 
MDR-TB and XDR-TB. In 2013, WHO has estimated 20.5% of 
previously diagnosed and 3.5% of newly diagnosed to be MDR-TB 
which translates to 480,000 patients. Of which 9.0% were XDR-TB[2]. 
 Third, is the occurrence of nontuberculous mycobacterial 
infection in immunocompetent and immunocompromised patients, 
which simulate the clinical features of Mycobacterium tuberculosis but 
are non-responders to anti-tuberculous therapy. Lack of better 
differentiating tools, lack of treatment guidelines and resistance to anti 
tuberculosis therapy imposes a challenge in differentiating between 
MTB and NTM[5]. 
The prevalence of ocular tuberculosis is highly variable given the 
absence of definitive diagnostic guidelines. It ranges from 0.39 to 9.86% 
in South and North India respectively. India has reported the largest 
number of tuberculous uveitis cases in the world.  
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Figure 2: WHO estimate of TB incidence rate in 2015 
 
4. MICROBIOLOGY: 
4.1 Mycobacterium tuberculosis: 
Mycobacterium tuberculosis is a slow-growing (with a doubling 
time of 15-20 hours while most bacteria have 1hour or less), obligate 
aerobe, facultative intracellular, non-sporing, non-motile, acid-fast 
bacilli[6]. Acid-fastness is ascribed to the presence of unsaponifiable 
wax, mycolic acid, which gives integrity to the cell, protecting against 
desiccation and is a key virulence factor. They are resistant to dry 
environment and viable in expectorated sputum for several weeks and is 
an important factor in the transmission of infection. They are either 
straight or slightly curved bacilli measuring 3µm × 0.3 µm occurring 
singly, paired or in clumps [Figure3]. Humans are the only natural 
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reservoir and infection is mainly by airborne respiratory aerosol. In 
immunocompetent individuals the bacilli can evade the macrophages 
and stay dormant causing a LTBI with a potential to re-activate when 
the immune system is compromised. The bacilli enter the lung where 
they are contained by the alveolar macrophages which expresses Toll-
like receptors and forms phagolysosome by fusion with lysosome 
exposing them to acidic environment, lysosomal enzymes and reactive 
oxygen species causing their death. When the balance between virulence 
of the bacilli and host immune system is altered it spreads to other 
oxygen rich tissues such as kidney, meninges, bones, eye and choroid 
causing extra-pulmonary tuberculosis.  
4.2 Drug Resistant Strains: 
 Development of drug resistant strains of Mycobacterium 
tuberculosis has been solely attributed to spontaneous chromosomal 
mutation because of absence of plasmids and transposons. Mutations in 
gene katG and inhA[7]encoding for Catalase peroxidase and Enoyl ACP 
reductase respectively which inhibit mycolic acid biosynthesis cause 
INH resistance. Mutations in rpoB[8] gene coding for β subunit of RNA 
polymerase which inhibit RNA synthesis cause Rifampicin resistance. 
4.3 Mycobacterium tuberculosis in eye: 
Within the eye the preferred sites are choroid, ciliary body and 
RPE. Recent histopathological studies along with real time PCR has 
demonstrated the bacilli in RPE, which shares the property of alveolar 
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macrophages in expressing Toll-like receptors and phagocytosis. Rao et. 
al.[9] have demonstrated Mycobacterium tuberculosis within RPE in a 
panuveitis case. Present studies report that recurrence in tuberculous 
choroiditis could be from reactivation of the bacilli in RPE and constant 
exposure of antigen. This contemplates in extending the duration of 
treatment with anti-tuberculous therapy preferably 6-9 months to 
prevent recurrences by eliminating the sequestered antigens. 
 
 
 
 
 
 
 
Figure 3: Electron-microscopic picture of Mycobacterium tuberculosis 
   
5. IMMUNOPATHOGENESIS: 
Infection with Mycobacterium tuberculosis induces adaptive cell-
mediated immunity.  Macrophages, CD4+ T cells, CD8+ T cells and 
cytokines such as IFN-γ, IL-12, IL-6 and TNF-α are the lead players in 
immunity against the bacilli. The bacilli on entering the body are 
presented to the macrophages and dendritic cells through TLRs. 
Activated macrophages produce IL-12 and TNF-α. IL-12 activates Th1 
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cell mediated immune response which in turn recruits CD4+ T cells to 
contain the bacteria[Figure 4]. 
5.1 Role of Macrophages: 
Mycobacterium tuberculosis on entering macrophages through 
TLRs, the phagosome fuse with lysosome forming phagolysosome 
where they are exposed to detrimental environment leading to the death 
of the bacilli. The phagolysosome have an acidic pH due to hydrolases, 
reactive oxygen species (ROS), reactive nitrogen intermediates (RNI) 
and lysosomal enzymes[10]. Virulent bacilli prevent phagosome fusion 
with lysosome and survive intracellularly, lying dormant until suitable 
conditions arise for its multiplication and evasion. Infected macrophages 
undergoes TNF-α mediated apoptosis. Activated macrophages produce 
IL-12 which activates Th1 immune response. Thus macrophages contain 
infection by phagolysosome formation, apoptosis and by activating cell 
response. 
5.2 Role of CD4+ T cells:  
Mycobacterium tuberculosis being sequestered as an intracellular 
pathogen, the antigens are presented to CD4+ T cells by the Major 
Histocompatibility Complex II (MHC-II). These cells are essential in the 
protective mechanism against Mycobacterium tuberculosis. In 
populations with decreased CD4+ T cells as in HIV infected patients, 
the susceptibility for infection and reactivation is greatly increased. The 
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main function of CD4+ T cells is production of IFN-γ and other 
cytokines for activation of macrophages[11][12]. 
 
Figure 4: Immunopathogenesis of Tuberculosis[13] 
 
5.3 Role of Cytokines: 
 IL-12 is produced by Mycobacterium tuberculosis phagocytosed 
activated macrophages. They induce Th1 cell immune response which 
produces IFN-γ. 
 IFN-γ is produced by the CD4+T cells which plays an important 
role in containing the infection. It is a major activator of macrophages 
and augment antigen presentation to CD4+ cells. 
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 Other cytokines are TNF-α, IL-1. IL-2, IL-4, IL-6, IL-10 and 
TGF-β which play complex and important role in the cell mediated 
immunity against the bacilli. 
5.4 Clinical importance of TNF-α: 
 The use of biological agents such as anti-TNF therapy 
(Infliximab) in diseases such as rheumatoid arthritis and HLA-B27 
Spondyloarthropathies has highlighted the importance of this cytokine in 
tuberculosis[14]. The use of these agents has led to an increase in the 
incidence of tuberculosis.  Hence careful evaluation and monitoring has 
to be done for patients on this therapy. 
5.5 Mycobacterium tuberculosis defense against host: 
The mechanism through which Mycobacterium tuberculosis 
evades host immune response is complex yet simple affecting in every 
subsequent step. The various impressive strategies are[15]:  
1) Unique ability to delay the initiation of cell mediated immune 
response by 2-3 weeks. This is possible by the failure of dendritic cells 
to migrate to regional lymph nodes.  
2) Inhibits the formation and maturation of phagolysosome 
3) Inhibits autophagy 
4) Decreases IFN- γ receptor mediated signaling, a major 
immune response against Mycobacterium tuberculosis. 
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6. PATHOGENESIS AND HISTOLOGY: 
 Phagocytosis by the macrophages is the first event in the 
complex series of host-pathogen relationship. Cell mediated immunity 
develops in 2-6 weeks of infection with influx of lymphocytes and 
activated macrophages at the site of lesion forming a granuloma. The 
growth of bacilli is checked and dead macrophages form caseum with 
dead bacilli in their centers. The granuloma functions as a reservoir for 
the bacilli and multiplication resumes once the host defense mechanism 
wall comes down leading to hematogenous spread. Fibrosis is the last 
event, surrounding the caseous necrosis to seclude the infection when 
other mechanism fails[16]. 
6.1 Pathogenesis in Eye: 
 Recent developments tend to resolve the debate between 
immune-mediated responses and bacteria-mediated immune responses. 
Direct role of Mycobacterium tuberculosis has been supported by 
Polymerase chain reaction (PCR) that has amplified Mycobacterium 
tuberculosis genome in 70% of clinically suspected intraocular 
tuberculosis and the significant decrease in recurrence of inflammation 
with anti-tuberculous therapy in presumed ocular tuberculosis compared 
to steroids alone. Thus, extrapolating the pathogenesis of extra-
pulmonary to intraocular tuberculosis three stages are identified: 
1) Bacterial dissemination 
2) Localization in ocular tissues 
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3) Bacterial re-activation and initiation of inflammation. 
Recently, the process of reactivation of chronic infection has been 
attributed to mycobacterial secreted proteins called as “resuscitation-
promoting factors”[17].  
Differences in pathogenesis between endemic and non-endemic 
population has been postulated to either re-infection or reactivation. This 
can be differentiated by DNA fingerprinting of mycobacterium bacilli 
isolates from recurrent tuberculosis patients. If the patterns are same in 
the subsequent episodes they suggest reactivation, if different then re-
infection. 
Granuloma is the primary lesion of mycobacterium and the crucial 
site of immunity. Recent studies suggest that granuloma are dynamic 
and trafficking of immune cells into and out occurs with a potential risk 
for dissemination. The choroidal granuloma are hypoxic and show 
expression of VEGF in retina and RPE. 
6.2 Histopathology: 
Histopathologically, the lesions contain granulomatous lesion with 
caseous central necrosis and occasional mycobacteria. The granuloma 
consists of epithelioid histiocytes, few horse-shoe shaped Langerhans 
type giant cells and mononuclear cells, primarily lymphocytes[Figure 
5]. Necrosis can involve iris and ciliary body and clinically present as 
pigmented hypopyon[18]. 
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Figure 5: Choroidal granuloma with lymphomononuclear infiltrate 
 
7. CLINICAL PRESENTATIONS: 
Tubercular uveitis is the most common infectious cause of uveitis 
worldwide. It has a wide spectrum of clinical presentation and its 
anatomical classification is given [Figure 6]. It can present as unilateral 
or asymmetrically bilateral with an insidious and chronic course and 
more often recurrent if treated with corticosteroids alone. 
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Figure 6 : Anatomical Classification of Tubercular uveitis with varied 
lesions 
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7.1 ANTERIOR UVEITIS: 
 Tubercular uveitis presenting as anterior uveitis are frequently 
asymmetrically bilateral, granulomatous and recurrent but unilateral 
non-granulomatous forms can also occur. Coles et.al.[19] wrote that 
tuberculosis should be suspected not only in granulomatous uveitis but 
also in patients with intense non-granulomatous uveitis of acute 
duration, relapsing uveitis or chronic smoldering disease form. 
Granulomatous forms are characterized by large mutton-fat keratic 
precipitates, broad based synechiae [Figure 8]and nodules in iris 
pupillary border (Koeppe) and on the surface (Bussaca). There can be 
formation of granuloma in the angle or a pigmented hypopyon following 
necrotic iris lesion. In patients with HIV, tuberculous uveitis has a 
dramatic picture depending on the CD4+ count[Figure 7]. 
7.1.1Complications of anterior uveitis: 
In chronic recurrent forms seclusio pupillae can occur leading to 
iris bombe and secondary angle closure glaucoma. Other complications 
in longstanding cases include formation ofcomplicated cataract, calcific 
band-shaped keratopathy, iris neovascularization and hypotony. 
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Figure 7: Granulomatous tuberculous uveitis in HIV-infected patient 
 
 
 
 
 
 
 
 
 
 
Figure 8 : Broad based posterior synechiae with mutton-fat Keratic 
precipitates 
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Figure 9 :  Grade 2 aqueous flare in acute anterior uveitis 
 
 
 
 
 
 
 
 
Figure 10: Granulomatous uveitis with mutton-fat Keratic Precipitates 
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Figure 11: Iris nodule (blue arrow) 
 
7.2 INTERMEDIATE UVEITIS: 
 Tubercular uveitis presents as intermediate uveitis where cells in 
vitreous along with snowballs in pars plana occur[Figure 12]. In severe 
forms of intermediate uveitis, cells spill into the anterior segment 
causing a spill-over anterior uveitis. Intermediate uveitis can be 
unilateral or asymmetrically bilateral. Relapsing chronic forms should 
lead to a high degree of suspicion for tubercular etiology. Severe vitritis 
presents with snowball opacities and snow banking and can be 
associated with peripheral retinal vasculitis. 
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7.2.1 Complications of intermediate uveitis: 
In chronic form of the disease, defective vision may be due to 
cystoid macular edema and epiretinal membrane formation. Secondary 
vitreous hemorrhage due to traction can occur in long-standing cases. 
 
 
 
 
 
 
 
Figure 12: Snow ball opacities in a patient with tuberculous 
intermediate uveitis 
 
 
 
 
 
 
 
Figure 13: Snow ball opacities in patient with tuberculous 
intermediate uveitis 
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Figure 14: Grade 4 vitritis in a patient with recurrent presumed TB 
intermediate uveitis 
 
7.3 POSTERIOR UVEITIS: 
Posterior tuberculous uveitis can manifest in various forms 
depending on the structures involved.  
7.3.1 Optic Nerve involvement: 
1) Papillitis: 
Papillitis can present as a single entity or as part of tuberculous 
meningitis causing an inflammation of the optic chiasma and optic 
nerve[20]. Patients present with acute decrease in vision, and are usually 
unilateral in presentation and rarely bilateral. On examination optic disc 
is hyperemic and edematous with indistinguishable margins with a 
frequent peripapillary serous retinal detachment[Figure 16]which can 
extend to the macula further decreasing the vision[Figure 17]. These 
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patients respond very well to anti-tuberculous therapy and show 
improvement in vision even before starting corticosteroids.To establish 
the diagnosisof tuberculous etiology Gupta et. al.[21] recommended 
criteria based on the clinical picture, response to anti-tuberculosis 
treatment, positive TST, positive IFN-γ. 
 
 
 
 
 
 
 
Figure 15: Tuberculous papillitis with peripapillary serous retinal 
detachment 
 
 
 
 
 
 
 
Figure 16: Tuberculous papillitis with serous macular detachment 
same patient as of figure 16 
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Figure 17: Early arterio-venous phase of FFA showing leakage from 
disc 
 
 
 
 
 
 
 
 
 
 
Figure 18: Late Phase of FFA showing pooling of dye at macula 
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2) OPTIC NERVE TUBERCULOMA 
Mycobacterium tuberculosis can infect the optic nerve 
causing optic nerve tuberculoma and are usually part of miliary 
disease[22]. In 1862, Cruveilhier described the first case of 
tuberculoma involving the optic nerve[23]. They can present as part of 
CNS disease and a CT Brain is requested to look for CNS 
tuberculoma. 
OCULAR TOXICITY OF ANTI-TUBERCULOUS DRUGS: 
 Another major concern is the drug related toxicity of 
antitubercular drugs. Ethambutol is the most common drug but Isoniazid 
and Streptomycin are also known to cause ocular toxicity. They present 
with decrease vision, defective red-green color vision and central or 
ceco-central scotomas. Ethambutol causes optic neuritis, more 
commonly retro-bulbar neuritis and is reversible with prompt 
discontinuation of drug. Isoniazid rarely causes retro-bulbar neuritis and 
can be bilateral. Defective vision even after discontinuation of drugs for 
3 months, toxicity due to INH is presumed. Streptomycin causes 
pseudotumor cerebri[24][25]. 
 Prophylactic treatment with pyridoxine is initiated to prevent the 
drug-related neurotoxicity of INH. 
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Box1: Various forms of optic nerve involvement in tuberculous 
optic neuropathy 
OPTIC NERVE INVOLVEMENT IN 
TUBERCULOUS OPTIC NEUROPATHY[26] 
Papillitis 
Optic Nerve Tuberculoma 
Compressive Optic Neuropathy 
Anterior ischemic optic neuropathy 
Retrobulbar neuritis 
Papilledema 
Neuroretinitis 
 
7.3.2 CHOROIDAL INVOLVEMENT: 
1) CHOROIDAL TUBERCULOMA: 
Choroidal tuberculoma are large granulomatous infiltrative lesion 
of the choroid by the tubercle bacilli, presenting as sub-retinal mass 
varying in size from 4 – 14 mm. Clinically they appear as creamy 
yellow elevated lesions accompanied by minimal vitritis[27][28][Figure 
19]. Retinal folds or retinal hemorrhages may be present and if adjacent 
to optic disc, disc edema is also present. Studies have shown that 
choroidal granuloma have hypoxic center which is a source of VEGF 
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leading to the formation of retino-choroidal anastomosis[29][Figure 20], 
a feature favoring the diagnosis but not pathognomonic of tuberculous 
etiology.  
 
 
 
 
 
 
 
 
 
Figure 19: Choroidal tuberculoma of the left eye 
 
 
 
 
 
 
 
 
 
Figure 20: Choroidal tuberculoma with retinal folds and 
retinochoroidal anastamosis (blue arrow) 
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Figure 21: Chotoidal tuberculoma of the left eye with disc edema 
 
 
 
 
 
 
 
 
 
 
Figure 22: Healed choroidal tuberculoma with chorio-retinal scar 
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Figure 23: FFA: Early arterio-venous phase showing 
hypofluorescence at the lesion and mild hyperfluorescene due to 
leakage 
 
 
 
 
 
 
 
 
 
Figure 24: FFA: Late arterio-venous phase showing 
hyperfluorescence 
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Differential diagnosis of Choroidal Tuberculoma are: 
1) Choroidal amelanotic melanoma 
2) Choroidal hemangioma 
3) Sarcoid granuloma 
4) Choroidal metastasis 
FFA in Choroidal Tuberculoma: 
 Early hypofluorescence due to necrotic lesion with late 
hyperfluorescence due to leakage [Figure 23, 24]. 
ICG in choroidal tuberculoma: 
 The lesion appears hypofluorescent in all phases due to masking 
effect of the choroidal granuloma and becomes less hypofluorescent 
following treatment[30]. The number of lesions seen in ICG can be more 
than ophthalmoscopic examination and larger than the lesion seen in 
FFA. 
Natural course of choroidal tuberculoma: 
 If left untreated, choroidal tuberculoma can extend to sclera 
causing fluid accumulation in the sub-tenon space and it can rupture into 
vitreous  leading to panuveitis. 
 Post treatment with ATT and steroids they heal leaving a chorio-
retinal atrophic scar. 
Complications: 
 Choroidal granuloma even following treatment can develop 
choroidal neovascularization membrane and hence a constant follow-up 
with FFA and OCT is required.  
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2) CHOROIDITIS: 
 Tuberculous choroiditis can involve retina causing chorioretinitis 
with marked vitritis. They present as creamy yellow lesion with 
indistinct margins [Figure 26, 27].In immunocompromised patients it 
can present as multifocal choroiditis[31].  
FAF in choroiditis: 
 Active lesions are hyper-autofluorescent at the margins. Healed 
lesions have a hypo-auto fluorescent margin. FAF is used as a novel 
non-invasive technique during follow-up to assess the response to 
therapy and detect recurrence.  
FFA in Choroiditis: 
 Active lesions show an early hypofluorescence with late 
hyperfluorescence. Healed lesions show an hyperfluorescent margin due 
to staining surrounding an hypofluorescent area[Figure 28,29,30,31]. 
ICG in Choroiditis: 
 Active lesions show early hypofluorescence which continue to be 
hypofluorescence in the late phase. 
On treatment they heal with a chorio-retinal scar. 
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      Figure 26: Multiple active     Figure 27: Healed Choroiditis  
                Choroiditis lesion            lesion with atrophic scar 
 
 
               
 
   
 
 
        Figure 28: Early phase in         Figure 29: FFA showing  
  FFA showing hypofluorescence             staining of the scar 
        corresponding to active  
           choroiditis lesion 
     
 
 
 
 
 
      Figure 30: Late phase in FFA     Figure 31: Late phase showing 
        showing hyperfluorecence               staining of the scar 
            of the choroiditis lesion 
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3) CHOROIDAL TUBERCLE 
Choroidal tubercle can present as unilateral or bilateral and single or 
multiple lesions frequently away from the posterior pole and as part of 
disseminated disease. They appear as orange-yellow lesion with 
indistinct margin and are not accompanied by inflammation[Figure 31]. 
Patients are usually asymptomatic since the lesions does not involve the 
macula. The lesions are histologically similar to tubercular granuloma 
presented anywhere else in the body. After ATT, the lesions fade 
completely leaving a flat hypopigmented scar. 
 
 
 
 
 
 
Figure 31: Choroidal tubercle seen in the periphery 
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4) SERPIGINOUS-LIKE CHOROIDITIS 
Serpiginous-like choroiditis presents as a grayish yellow lesion in 
the posterior pole with creeping snake-like activity. Both healed and 
active stages of the disease are found in the same eye because of its 
propensity to recur from its edges[Figure 32]. Frequently they are 
bilateral with significant vitreous inflammation and in few casescan 
present as panuveitis. Vision is mildly decreased because of vitritis and 
is fairly maintained until the lesion involves the fovea sometimes almost 
at last stage where patients present with extensive healed and active 
lesion[Figure33]. They must be differentiated from the autoimmune 
etiology of multifocal serpiginous choroiditis where the lesions start at 
in the juxta papillary region and extends in the posterior pole. 
Serpiginous-like choroiditis is thought to be a hypersensitive reaction to 
tubercle bacilli residing in RPE. Patients responds well to 
immunosuppressive therapy[32][33]. Recurrence rate is reduced by 
suspecting its tubercular etiology and starting ATT. 
FAF in Serpiginous like choroiditis: 
Active lesions present with hyper-autofluorescent margin. Healed 
lesions have hypo-autofluorescent margin. 
FFA in Serpiginous like choroiditis: 
Active lesions present with early hypofluorescence and late 
hyper-fluorescence. Healed lesions show window defect due to RPE-
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choriocapillary complex atrophy or blocked fluorescence due to retinal 
pigment epithelium proliferation. 
ICG in Serpiginous like choroiditis: 
Active lesions are hypofluorescent from early to late phases. 
Complications in Serpiginous like choroiditis: 
Irreversible vision loss occurs late in Serpiginous like choroiditis 
due to involvement of the fovea causing a chorioretinal atrophy. Vision 
loss after treatment can occur due to development of choroidal 
neovascular membrane and sub retinal fibrosis. 
 
 
    Figure 32: Serpiginous-like       Figure 33: Chorioretinal atrophic 
   choroiditis with active lesions  patch same eye of figure 32 
              at the edges     
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7.3.3 RETINAL INVOLVEMENT 
RETINAL VASCULITIS: 
Retinal vasculitis of tubercular origin is due to hypersensitivity 
reaction to the tubercular bacilli, and presents more commonly as a 
periphlebitis[34][Figure34]. They can present with or without a 
chorioretinal lesion. The presence of an active or healed choroiditis 
patch is highly suggestive of a TB etiology. Clinically perivascular 
cuffing of exudative materials is present and if extensive can lead to 
occlusion and ischemia causing neo-vascularization. Other causes such 
as Systemic Lupus Erythematosus, Sarcoidosis, Behcet’s disease should 
be excluded even in areas endemic for tuberculosis. Tuberculous retinal 
vasculitis can present in three forms: 
1) retinal vasculitis with overlying choroiditis 
2) isolated retinal vasculitis 
3) Eales’s disease 
Complications of retinal vasculitis: 
 Retinal vasculitis can cause neovascularization, non-resolving 
vitreous haemorrhage, epimacular membrane and tractional retinal 
detachment. 
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Figure 34: Colour fundus photography showing periphlebitis. 
FFA in retinal vasculitis: 
 Active lesions show vessel wall staining and if occlusive, 
hypofluorescent capillary non-perfusion with or without retinal or disc 
neo-vascularization [Figure 35]. FFA also helps in identifying cystoid 
macular edema. 
 
 
 
 
 
 
 
Figure 35: FFA showing vessel wall staining along with capillary 
non-perfusion areas 
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7.4  ENDOPHTHALMITIS AND PANOPHTHALMITIS: 
 Miliary tuberculosis with hematogenous spread of tubercle bacilli 
infects all layers of the eye leading to panophthalmitis. They are seen in 
severely immunocompromised patients such as HIV infection[35]. They 
present as acute onset with corneal infitration and intense anterior 
chamber reaction and hypopyon along with post segment manifestation 
[Figure 36]. Occasionally, a large choroidal tuberculoma can burst into 
the vitreous producing endophthalmitis and can involve sclera producing 
panophthalmitis. 
 
 
 
 
 
 
 
 
Figure 36 Endophthalmitis in a case of miliary tuberculosis in HIV 
infected patient 
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8. INVESTIGATIONS: 
 
Figure 37: Flowchart of various investigations available to diagnose 
tubercular uveitis 
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8.1 TUBERCULIN SKIN TEST: 
 Mantoux test is a classic delayed type IV hypersensitivity 
reaction in persons  previously exposed to the tubercle bacilli[36]. A 
purified protein derivative (PPD) containing >200 proteins of 
Mycobacterium species is used. Mantoux test has limited specificity and 
are positive when exposed to environmental nontuberculous 
mycobacterium. They are weakly positive in BCG vaccinated 
individuals and this factor should be considered in Asia, Latin America 
and Africa where BCG vaccine is common. PPD are available in three 
strengths low (1 TU), medium (5 TU) and high strength (250 TU)and 
are used depending on the endemicity and high-risk individuals. It has a 
sensitivity of 75-90% where 10% of individuals in spite of tuberculous 
disease show negative results.  
 
 
 
 
 
 
 
 
Figure 38: Positive Mantoux test showing induration 
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Technique of Mantoux Test: 
Medium strength 5 TU in 0.1ml of PPD is injected intradermally 
on the volar aspect of the forearm producing a wheal of 6-10mm and 
induration is read 48-72 hours although readings after 96 hours if 
positive is significant. 
Interpretation of Mantoux test: 
 The amount of induration by palpation and not erythema is 
measured transversally[Figure38]. Formation of bullae, vesicles and 
necrosis indicates increased sensitivity and the presence of infection. 
Larger the reaction, more specific for infection with MTB, smaller 
reactions are probably due to NTM. Persons with larger reaction are at a 
higher risk of developing the disease. 
 <5mm –  Negative 
 5-9mm – positive in following individuals: 
 HIV infection 
 Organ transplant recipients 
 End stage renal disease 
 On long term steroid therapy >6weeks 
 Recent contact with active tuberculosis patients 
 >10mm – positive in following individuals: 
 Health care professionals 
 Children  
 Endemic regions 
41 
 
 Intravenous drug users 
 Diabetes, leukemia 
>15 mm – Positive in all individuals with no known risk factors. 
Limitations of Mantoux results: 
1) False negative in immunocompromised individuals can reach up 
to 50% in patients with HIV infection, disseminated tuberculosis, 
malignancies, sarcoidosis and immunosuppressive therapies. 
2) Booster effect seen in previously tested individuals. 
3) Cross reactivity with BCG vaccination and environmental NTM. 
 
8.2 INTERFERON- GAMMA ASSAY TESTS: 
Genomic sequencing of Mycobacterium tuberculosis in the recent 
decade has led to the recognition of genomic regions present in MTB 
that are deleted from M.bovis in the preparation of BCG vaccine and 
absent in mostenvironmental nontuberculous mycobacteria. Among the 
antigens that elicit vigorous cell mediated immunity the three antigens 
used in the assays are ESAT-6 (Early Secretory Antigenic Target – 6) 
and CFP-10 (Culture Filtrate Protein – 10) and TB7.7. These two 
antigens are used in the development of invitro tests to identify cellular 
immunity to tuberculosis. Two novel tests have been introduced, using 
enzyme linked immunosorbent assay (QuantiFERON®-TB Gold test) 
and enzyme-linked immunospot assay (T-SPOT®.TB)[37]. 
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8.2.1 QuantiFERON-TB GOLD TEST: 
 QuantiFERON®-TB GOLD test and the more simplified 
QuantiFERON®-TB In-tube test developed as an overnight test are done 
using enzyme-linked immunosorbent assay. They quantify the amount 
of IFN-gamma release by the sensitized T-cells on exposure to the 
antigens ESAT-6, CFP-10 and TB7.7[38].Hence the assay is dependent 
on host immune status. Pooled sensitivity and specificity of the test for 
diagnosing MTB infection are 78-83% and 98-100% in developing 
countries. 
8.2.2 T-SPOT.TB TEST: 
 T-SPOT.TB® TEST is an enzyme-linked immunospot assay and 
quantifies the number of IFN-gamma producing T-cells on exposure to 
ESAT-6 and CFP-10[39]. The test is still under evaluation by FDA and 
approved in Europe. 
Advantages of IFN-gamma release assays: 
1) They are more specific than the tuberculin skin test because 
false-positive rates due to prior BCG vaccination and cross-
reactivity due to NTM are decreased. 
2) Single visit test 
Limitations of IFN-gamma release assays: 
1) Like Mantoux test they depend on the host immune status. 
2) Positive results indicate either active or latent tuberculosis and 
does not indicate disease. 
3) More expensive 
43 
 
8.3 CHEST XRAY AND HIGH-RESOLUTION CT CHEST 
(HRCT): 
 Chest X-ray and HRCT are useful in detecting the systemic 
involvement of tuberculosis as lungs are entrant to the organisms. 
Radiological features suggestive of tuberculosis are cavities, miliary 
infiltrates, hilar lymphadenopathy, fibrosis and effusions. Lesions are 
more common in the upper lobes because of high partial pressure of 
oxygen. HRCT Chest is superior to chest X-ray in early detection of 
lesions especially minimal exudative tuberculosis and determining 
disease activity differentiating active lesions from old fibrotic lesions[40]. 
 
8.4 MICROBIOLOGICAL: 
8.4.1 ACID-FAST ZIEHL-NEELSEN STAIN: 
 A definite diagnosis of tuberculosis is made on demonstrating M. 
tuberculosis in ocular fluids either aqueous or vitreous samples. 
Techniques for aqueous and vitreous sampling: 
Aqueous sample provides a limited quantity though can prove 
valuable.  0.2 ml of aqueous is obtained after paracentesis under topical 
anesthesia performed at a slit-lamp or microscope. Complications such 
as keratitis, hyphema, cataract and endophthalmitis can occur. 
Vitreous fluid sampling is more tedious than aqueous but 
provides larger sample material and requires an operating theatre. Under 
subtenon or peribulbar anesthesia, 0.5-0.7 ml of undiluted vitreous 
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sample is obtained either through vitreous biopsy or vitrectomy using 
three-port vitrectomy. 
Principle of Acid-fast stain: 
 When smear is stained with the carbol fuchsin dye and heated, it 
solubilizes the lipoid cell wall and enters the cytoplasm. On applying 
decolorizing agents such as 3%HCL in 95%alcohol the lipoid cell wall 
resists decolorization and hence appear red[Figure 39]. Whereas non-
acid-fast bacteria lack lipoidal cell wall and decolorizes and is 
counterstained with methylene blue and appear blue. 
 
 
 
 
 
 
 
Figure 39: Ziehl-Neelsen staining showing pink Mycobacterium 
tuberculosis 
Other stains available for staining Mycobacterium tuberculosis 
are Auramine rhodamineand Kinyoun’s modification of acid-fast 
staining. 
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8.4.2 MYCOBATERIUM TUBERCULOSIS CULTURE: 
 
 
 
 
 
Figure 40:  L-J medium showing M.tb colonies 
 
 Culture method is highly sensitive and can detect as few as 10-
100 bacilli per ml.Mycobacterium tuberculosis has a slow doubling time 
and take weeks to grow and are termed culture negative when no growth 
is seen even after 8-12 weeks. The various culture media used are: 
1. Solid media: - Lowenstein-Jensen medium [Figure 40] 
2. Liquid media: - Middlebrook 7H10/7H111 
3. Automated systems: - BACTEC 9000MB and BACTEC MGIT 
BACTEC use fluorescence system and helps in rapid diagnosis of 
growth by 2-3 weeks. Radiometric method is the fastest and sensitive 
cultural tool for diagnosis of Mycobacterium tuberculosis. 
  
8.5 MOLECULAR ASSAYS:  
8.5.1 NUCLEIC ACID AMPLIFICATION TECHNIQUES: 
Polymerase Chain Reaction is a test used to amplify selective 
pieces of DNA or RNA invitro and has emerged as powerful rapid tool 
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to diagnose mycobacterial genome in ocular fluids such as aqueous, 
vitreous and subretinal fluid. It has high specificity and variable 
sensitivity since the number of infected cells in ocular fluids are low. 
Rao et al has studied the presence of MTB residing in RPE and detection 
of mycobacterial genome helps in directing specific therapy. Only 37% 
of presumed ocular tuberculosis had a positive PCR[41].The various 
types of PCR include: 
1. Conventional PCR 
2. Real time or Quantitative PCR (qPCR) 
3. Nested PCR 
4. Mutiplex -PCR 
The common gene sequences used in PCR for ocular tuberculosis 
are MPB64 gene, IS6110 gene and Pab (Protein b) which are specific for 
Mycobacterium tuberculosis. IS6110 are absent in 10-40% of the 
isolates and lead to false-negative results. Hence, nested PCR with 
IS6110 and MPB64 has a higher sensitivity than single-target IS6110 
alone. qPCR quantifies the amount of genome and is directly 
proportional to the load of infection. 
 
 
 
 
 
47 
 
 
 
 
 
 
 
Figure 41: PCR using MPB64 and IS6110 genome 
Limitations of PCR: 
 Expensive and needs a complex laboratory set-up. 
8.5.2 GeneXpert MTB/RIF TEST: 
 Xpert® MTB/RIF assay is a newer nucleic acid amplification 
method which detects the bacilli and also its resistance against 
rifampicin. The test detects the MTB DNA in less than 2 hours and 
genetic mutations responsible for rifampicin resistance[42]. This can 
revolutionize the treatment of tuberculosis and can contribute in 
containing the transmission of disease. 
9.OCULAR IMAGING 
9.1  FUNDUS AUTOFLUORESCENCE: 
This novel non-invasive retinal imaging helps in detecting active 
from healed lesions useful in assessing response to treatment and 
recurrence in follow up. FAF maps the predominant ocular fluorophore, 
lipofuscin, which deposits due to increased metabolism in inflammatory 
conditions. In tuberculous uveitis they are useful in choroiditis lesions 
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where active regions are hyper-autofluorescent at their margins[Figure 
42]. 
 
 
 
 
 
 
 
 
Figure 42: FAF hyper-autofluorescence seen at the active edges of 
choroiditis 
 
9.2 FUNDUS FLUORESCEIN ANGIOGRAPHY  
FFA is a useful tool in the diagnosis of posterior segment lesions. 
It helps in the anatomical classification and the early detection of 
complications such as development of choroidoal neovascular 
membrane, cystoid macular edema and retinal or disc 
neovascularisation. It evaluates the lesion based on their vascular pattern 
does not give clue to etiology. 
FFA in Choroiditis: 
 In choroiditis early arterio-venous phase shows hypoflurescence 
due to blockage of transmittance by the choroidal inflammation and in 
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late phase shows hyperfluorescence due to diffusion of 
dye[Figure42,43]. 
 
 
 
 
 
 
Figure 42: FFA : Early phase showing hypofluorescence 
 
 
 
 
 
 
 
Figure 43: FFA : Late phase showing hyperfluorescence 
FFA in Choroidal Tuberculoma: 
 Choroidal tuberculoma being a necrotic lesion and lacking a 
blood supply appear hypofluorescent in the early phase and become 
hyperfluorescent in the late stages and are usually accompanied by 
serous exudative retinal detachment surrounding the lesion which is seen 
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as pooling of dye and delineates its margin often larger than the clinical 
observation[Figure 44, 45]. 
 
 
 
 
 
 
Figure 44: FFA : Early hypofluorescence seen in choroidal 
tuberculoma 
 
 
 
 
 
 
 
Figure 45: FFA : Late hyperfluorescence seen in choroidal 
tuberculoma 
FFA in Serpiginous-like choroiditis: 
 In Serpiginous-like choroiditis early phase shows 
hypofluorescence in the areas of active edge of choroiditis and  window 
defect corresponding to areas of chorio-retinal atrophy with 
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transmittance of underlying larger choroidal vessels. In late phases 
hyperfluorecence is seen in the areas ofchoroiditis[Figure 46, 47]. 
 
 
 
 
 
 
 
Figure 46: Early phase showing hypofluorescence 
corresponding to choroiditis and also hypofluorescence corresponding 
to chorioratinal atrophy because of choriocapillaries atrophy 
 
 
 
 
 
 
 
 
 
Figure 47: Late phase showing hyperflurescnce corresponding 
to choroiditis patch and persistent hypoflurescence in areas of 
choriocapillaries atrophy 
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FFA in Retinal vasculitis: 
In vasculitis, FFA shows hyperfluorescence of the vessel wall 
due to staining.  Tubercular vasculitis can lead to occlusive vasculitis 
with hypofluorescent capillary non-perfusion areas in retina[Figure 48]. 
 
FFA on screening for late-complications of tubercular uveitis: 
 FFA is helpful in diagnosing cystoid macular edema[Figure 49], 
neovascularization and subretinal neovascular membrane formationeven 
in the presence of hazy vitritis media and help in diagnosis and early 
intervention. 
 
 
 
 
 
 
 
Figure 49: FFA showing cystoid macular edema in a petaloid pattern 
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9.3 INDOCYANINE GREEN ANGIOGRAPHY: 
 ICG is different from FFA in which the dye is 98% protein bound 
compared to 80% of sodium fluorescein and therefore leaks only in 
choriocapillaries. They fluoresce in infrared spectrum and unlike in FFA 
the fluorescence is not blocked by RPE and therefore is a useful tool in 
delineating choroidal vascular pathology. In tubercular choroiditis the 
active lesion remains hypofluorescent in all phases of ICG. 
 
9.4 OPTICAL COHERENCE TOMOGRAPHY: 
 OCT is a non-invasive rapid imaging test which provides in vivo 
cross-sectional study of the ocular structures. OCT is mainly useful in 
assessing the complications of the disease such as cystoid macular 
edema, epimacular membrane and sub-retinal neovascular membrane. 
 
10. MANAGEMENT  
 Management of tubercular uveitis depends on the diagnosis of a 
tubercular etiology. Failure to start the patient on anti-tuberculous 
therapy with immunosuppressive drugs not only causes recurrence of the 
disease but at times can be life-threatening causing a disseminated 
tuberculous disease. Challenges faced by the ophthalmologist lies in the 
lack of definite diagnostic guidelines because of varied presentation and 
limited ocular samples and the hesitant chest physician in starting the 
anti-tuberculous therapy. The US FDA has recommended 9 months 
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course of ATT in the treatment of extra-pulmonary tuberculosis[43]. The 
commonly used drugs are Isoniazid, Rifampicin, Pyrazinamide and 
Ethambutol. An intensive course of 2 months followed by maintenance 
course of 4-7 months duration is given. If following 2 months there is no 
improvement patient has to be reassessed and an alternate diagnosis or 
resistant forms should be suspected. 
Role of steroids and immunosuppressive drugs: 
 The main aim in tubercular uveitis is the reduction in 
inflammation. Steroids used in various routes of administration are 
topical, periocular and oral.Anti tuberculous drugs should be 
administered along with steroids since they reduce the microbial load 
and antigen reducing the chances of recurrence. 
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AIM AND OBJECTIVES 
AIM: 
 To study the risk group, diverse clinical presentation, course, 
diagnosis and management of tuberculous uveitis. 
PRIMARY OBJECTIVE: 
 To assess the frequency of occurrence of various forms of 
tuberculous uveitis, their effect on visual acuity and response to anti-
tuberculous therapy. 
SECONDARY OBJECTIVE: 
 To study age of presentation, sex predilection, associated risk 
factors, clinical presentation of tuberculous uveitis.  
STUDY DESIGN: 
 Prospective Descriptive Study 
SAMPLE SIZE: 
 30  
MATERIALS AND METHODS: 
INCLUSION CRITERIA: 
1) Patients with positive Mantoux Test i.e. 10mm or more 
induration at 48-72 hours with or without specific lesion in chest 
radiography. 
2) Evidence of active uveitis i.e. inflammatory cellular reaction in 
anterior chamber or keratic precipitates or vitreous cells or 
choroiditis or optic neuritis or retinal vasculitis. 
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3) Patients with positive contact history or known pulmonary or 
extra-pulmonary tuberculosis. 
EXCLUSION CRITERIA: 
1) Patients treated elsewhere for the presenting complaints. 
2) Patients with infectious uveitis other than tubercular etiology. 
3) Patients diagnosed as non-infectious uveitis. 
METHODOLOGY: 
 Patients presenting to Uvea and Retina services and who fulfilled 
the above inclusion and exclusion criteria were registered. After 
obtaining the consent and if less than 18 years’ consent taken from the 
parents, were included in the study.  
 A detailed history regarding the symptoms -  duration, course and 
recurrence, contact history and previous history of any forms of 
tuberculosis treated or untreated with anti-tuberculous therapy were 
noted. 
Systemic examination included cervical lymph nodes and 
respiratory system. Ocular examination included BCVA using Snellen 
chart converted to LogMar scale for statistical purpose, measuring 
intraocular pressure using Goldmann Applanation Tonometer, 
examination of anterior segment using slit-lamp and posterior segment 
using +90D biomicroscopy. Fundus Fluorescein Angiography was done 
when required. Laboratory investigations included hemoglobin, total 
blood count, differential blood count, erythrocyte sedimentation rate, 
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blood sugar, HIV-ELISA, VDRL, HLA-B27, Toxocara ELISA, TORCH 
serology tests, Tuberculin skin test and chest radiograph. Patients were 
referred to pulmonologist and were started on anti-tuberculous 
chemotherapy along with steroids either in oral, topical, periocular or in 
all forms. 
MANAGEMENT: 
 All patients, after chest physician opinion were started on anti 
tuberculosis therapy and corticosteroids. Choice of route of 
corticosteroids was made depending on the diagnosis. In patients with 
only posterior uveitis oral Prednisolone 1mg/Kg body weight was 
started initially and tapered according to responseand patients with 
intermediate uveitis periocular steroid injection Triamcinolone acetate 
was given. In patients with anterior uveitis topical 1% Prednisolone 
acetate suspension was added along with cycloplegic 2% Homatropine 
eye drops. 
FOLLOW-UP: 
 Patients were followed up in 2 weeks, 1 month and 3 months 
duration. Response to treatment was assessed using BCVA and decrease 
in intraocular inflammation. Complications such as secondary glaucoma, 
complicated cataract, vitreous opacities, worsening of inflammation, 
choroidal neovascular membrane and vitreous hemorrhage were looked 
for. 
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STATISTICAL ANALYSIS: 
 Patients data were entered in Excel spread sheet and statistical 
analysis was done using SPSS 16.0 Package. Statistical analysis 
included descriptive statistics, where mean and 95% confidence interval 
was calculated for continuous variables whereas percentages were 
calculated for categorical variables. A p value <0.001 was considered as 
statistically significant. Paired t-test was used to compare the continuous 
variable (mean visual outcome) before and after treatment at 2 weeks 
and 3 months. 
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RESULTS 
1.AGE DISTRIBUTION: 
 
 
 
 
 
 
 
 
Table 1: Age distribution among tubercular uveitis in this study 
Chart 1: Bar chart showing age distribution among tubercular 
uveitis in this study 
In this study, of the 30 patients, 5(16.7%) were in the age group 
15-24 years, 5(16.7%) in 25-34 years, 12(40.0%) in 35-44 years, 5(16.7) 
AGE IN YEARS NO. OF PATIENTS 
PERCENTAGE 
(%) 
15-24 5 16.7 
25-34 5 16.7 
35-44 12 40.0 
45-54 5 16.7 
55-64 2 6.7 
>65 1 3.3 
Total 30 100.0 
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SEX DISTRIBUTION
Female Male
in 45-54 years, 2(6.7%) in 55-64 years, 1(3.3%) >65 years. Maximum 
number of patients (40%) were in the age group between 35-44 years. 
The minimum age was 17 years and maximum age 66 years with a mean 
age of 38.63 years (S.D =11.82). 
2. SEX DISTRIBUTION: 
SEX NO. OF PATIENTS 
PERCENTAGE
(%) 
Female 11 36.7 
Male 19 63.3 
Total 30 100 
 
Table 2: Sex Distribution among tubercular uveitis in this study 
Chart 2: Pie-diagram showing sex distribution among tubercular 
uveitis patients in this study 
In this study, there were 11 female patients and 19 male. The 
male out-numbered the female with a ratio of 63.3% and female 36.7%. 
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3. DISTRIBUTION OF RISK OF OCULAR TUBERCULOSIS: 
 NO. OF PATIENTS 
PERCENTAGE 
(%) 
Contact History With TB 20 66.67 
Old Pulmonary TB 1 3.33 
Extrapulmonary TB 
History 5 16.67 
Miliary TB 4 13.33 
Total 30 100 
 
Table 3: Distribution of risk of Ocular Tuberculosis in this study 
Chart 3: Bar diagram showing distribution of risk of ocular 
tuberculosis in this study 
In this study, the incidence of ocular tuberculosis was higher in 
patients with exposure to or contact with tuberculosis (66.6%) followed 
by patients with previous extra-pulmonary tuberculosis (16.66%). 
13.33% patients had miliary tuberculosis at the time of diagnosis of 
ocular tuberculosis and 3.33% were treated for previous pulmonary 
tuberculosis. 
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4. AFFECTED EYE: 
EYE NO. OF PATIENTS 
PERCENTAGE 
(%) 
Both Eye 7 23.3 
Right Eye 10 33.3 
Left Eye 13 43.4 
Total 30 100 
  
Table 4: Laterality of the affected eye 
 
 
Chart 4: Bar chart showing laterality of the affected eye 
 
In this study, left eye was affected at an increased frequency 
43.3% followed closely by right eye 33.3% and both eye was affected in 
only 23.3% of the patients. 
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5. DEFECTIVE VISION: 
VISION CHANGES NO. OF PATIENTS PERCENTAGE 
Defective Vision 26 86.7 
No Defective Vision 4 13.3 
Total 30 100 
 
Table 5: Patients presenting with defective vision 
 
 
Chart 5: Bar chart showing patients presenting with defective vision 
 In this study, 26 patients (86.7%) complained of defective vision 
and 4 patients (13.3%) did not have decrease in vision and these patients 
had choroidal tubercles in the mid-peripheral or peripheral retina with 
miliary tuberculosis without signs of inflammation. 
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6. PAIN / REDNESS / PHOTOPHOBIA: 
PAIN/ REDNESS/ 
PHOTOPHOBIA 
NO. OF 
PATIENTS 
PERCENTAGE 
(%) 
Yes 3 10 
No 27 90 
Total 30 100 
 
Table 6: Patients presenting with pain / redness / photophobia 
 
 
Chart 6: Bar chart showing patients presenting with pain / redness / 
photophobia 
In this study, only 3 (10%) patients had complaints of redness, 
pain and photophobia, symptoms of anterior segment inflammation, 
remaining 27(90%) did not present with these symptoms. Of the three, 2 
patients presented as anterior uveitis and 1 patient presented with 
Serpiginous-like choroiditis with anterior segment inflammation. 
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7. COMPLAINTS OF FLOATERS: 
FLOATERS NO. OF PATIENTS 
PERCENTAGE 
(%) 
Present 10 33.3 
Absent 20 66.7 
Total 30 100 
 
Table 7: Patients presenting with Floaters 
 
Chart 7: Bar diagram showing patients presenting with floaters in this 
study 
 
In this study, 10(33.3%) patients complained of floaters, a 
symptom suggestive of vitritis and 20(66.7%) did not have floaters. Of 
the 10 patients, 5 patients had intermediate uveitis and 2 patients 
serpiginous-like choroiditis.  
66 
 
0
5
10
15
20
25
30
DEFECTIVE VISIONPAIN. REDNESS, PHOTOPHOBIAFLOATERS NIL COMPLAINTS
PRESENTING COMPLAINTS
8. PRESENTING COMPLAINTS: 
COMPLAINTS NO. OF PATIENTS 
PERCENTAGE 
(%) 
Defective Vision 26 86.7 
Pain. Redness, 
Photophobia 3 10.0 
Floaters 10 33.3 
Nil Complaints 4 13.3 
 
Table 8: Complaints of patients with tubercular uveitis 
 
Chart 8: Bar diagram showing various complaints among patients 
with tubercular uveitis in this study 
 
 In this study, 26 (86.7%) patients had defective vision, 3 (10.0%) 
patients had pain, redness and photophobia, 10 (33.3%) patients had 
complaints of floaters and 4 (13.3%) patients did not have any specific 
complaints and were screened during ophthalmological evaluation of 
miliary tuberculosis and they had peripheral choroidal tubercle on 
indirect ophthalmoscopic examination. 
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9. HISTORY OF RECURRENCE: 
HISTORY OF 
RECURRENCE 
NO. OF 
PATIENTS 
PERCENTAGE 
(%) 
Yes 6 20 
No 24 80 
Total 30 100 
 
Table 9: Recurrence among tuberculous uveitis 
 
Chart 9: Bar diagram showing recurrence among patients in this 
study 
 
In this study, 6(20%) patients had a history of recurrence of the 
disease. 24(80%) patients presented as a first episode. 
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10. DIAGNOSIS OF TUBERCULAR UVEITIS: 
DIAGNOSIS 
NO. OF 
PATIENTS 
PERCENTAGE 
(%) 
Anterior Uveitis 2 6.7 
Intermediate Uveitis 5 16.7 
Posterior Uveitis 22 73.3 
Panuveitis 1 3.3 
Total 30 100 
 
Table 10: Pattern of Tubercular uveitis 
 
 
Chart 10: Bar diagram showing various patterns of tubercular uveitis 
presented in this study 
 
In this study, tubercular uveitis presenting as posterior uveitis 
was the commonest presentation with 22 (73.3%) patients, followed by 
intermediate uveitis in 5 (16.7%) patients. 2 (6.7%) patients presented 
with anterior uveitis and 1 (3.3%) patient presented with panuveitis. 
 
69 
 
0 1 2 3 4 5 6 7 8
Choroiditis
Choroidal Tubercle
Choroidal Tuberculoma
Serpiginous-Like Choroiditis
Papillitis
Tuberculoma With Retinal Vasculitis
DISTRIBUTION OF POSTERIOR UVEITIS CAUSES
11. DISTRIBUTION OF UVEITIS IN POSTERIOR SEGMENT: 
DISTRIBUTION OF POSTERIOR 
UVEITIS 
NO. OF 
PATIENTS 
PERCENTAGE(%) 
AMONG 
POSTERIOR 
SEGMENT 
Choroiditis 7 30.4 
Choroidal Tubercle 5 21.7 
Choroidal Tuberculoma 7 30.4 
Serpiginous-Like Choroiditis 2 8.7 
Papillitis 1 4.4 
Tuberculoma With Retinal Vasculitis 1 4.4 
Total 23 100 
 
Table 11: Distribution of uveitis in posterior segment 
 
Chart 11: Bar-diagram showing distribution of various causes of 
uveitis in posterior segment involvement 
 In this study, of the 23 patients who had posterior segment 
involvement, choroiditis and choroidal tuberculoma had equal 
distribution with 7 (30.4%) patients each. They are closely followed by 
choroidal tubercle presented in 5 (21.7%) patients. Serpiginous-like 
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choroiditis was presented in 2 (8.7%) patients. Optic nerve tuberculoma 
and tuberculoma with retinal vasculitis was presented in 1 (4.4%) patient 
each. 
 
12. LATERALITY OF AFFECTED EYE (UNILATERAL VS 
BILATERAL): 
DIAGNOSIS  
LATERALITY OF 
AFFECTED EYE TOTAL 
BILATERAL UNILATERAL 
Anterior 
Uveitis 
No. of Patients 0 2 2 
Percentage 0% 100.0% 100.0% 
Intermediate 
Uveitis 
No. of Patients 4 1 5 
Percentage 80.0% 20.0% 100.0% 
Posterior 
Uveitis 
No. of Patients 3 19 22 
Percentage 13.6% 86.36% 100.0% 
Panuveitis 
No. of Patients 0 1 1 
Percentage 0% 100.0% 100.0% 
Total 
No. of Patients 7 23 30 
Percentage 23.3% 76.7% 100.0% 
 
Table 12: Laterality of Tuberculous uveitis 
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Chart 12: Bar diagram showing laterality of tuberculous uveitis 
  
In this study, 7(23.3%) patients had bilateral involvement of 
which 4 patients had intermediate uveitis and 3 patients had posterior 
uveitis. Anterior uveitis and panuveitis did not have bilateral 
presentation. 23 (76.7%) patients had unilateral involvement of which 
19 were posterior uveitis and 1 intermediate uveitis. All patients with 
anterior uveitis and panuveitis presented unilaterally. 
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13. CORRELATION OF VISION AT PRESENTATION WITH 
DIAGNOSIS: 
DIAGNOSIS  
VISION (BCVA) TOTAL 
6/6 6/9-6/12 
6/18-
60 <6/60  
Anterior 
Uveitis 
No. of 
Patients 0 1 1 0 2 
% 0% 50.0% 50.0% 0% 100% 
Intermediate 
Uveitis 
No. of 
Patients 0 0 4 1 5 
% 0% 0% 80.0% 20.0% 100.0% 
Posterior 
Uveitis 
No. of 
Patients 3 2 6 11 22 
% 13.6% 9.1% 27.3% 50.0% 100.0% 
Panuveitis 
No. of 
Patients 0 0 0 1  
% 0% 0% 0% 100% 100% 
Total No. of Patients 3 3 11 13 30 
 % 10.0% 10.0% 36.7% 43.3% 100.0% 
 
Table 13: Correlation of vision at presentation with diagnosis 
Chart 13: Clustered diagram showing correlation of vision at 
presentation with diagnosis 
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 In this study, severe defective vision <6/60 was present in 13 
(43.3%) patients of which 11 patients had posterior uveitis, 1 patient had 
intermediate uveitis and 1 patient panuveitis. 
 Moderate defective vision 6/18-6/60 was present in 11(36.7%) 
patients of which 6 had posterior uveitis, 4 had intermediate uveitis and 
1 patient had anterior uveitis. 
 Mild defective vision 6/9-6/12 was present in 3 (10.0%) patients 
of which 2 had posterior uveitis both the patients had peripheral 
choroidal tubercle sparing the macula with nuclear lens changes. 
Defective vision in these patients were attributed to the cataractous lens 
changes. And 1 patient had anterior uveitis. 
 No defective vision 6/6 was present in 3(10.0%) patients all of 
whom had a peripheral choroidal tubercle. 
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14. ESR ABNORMALITY IN TUBERCULAR UVEITIS: 
ESR AT 1 HOUR(mm) NO.OF PATIENTS 
PERCENTAGE 
(%) 
Raised 24 80.0% 
Within Normal Limits 6 20.0% 
Total 30 100.0% 
 
Table 14: ESR Abnormality in Tubercular uveitis 
 
 
Chart 14: Bar diagram showing ESR Abnormality in Tubercular 
uveitis 
In this study, ESR at 1 hour was raised in 24 (80.0%) patients and 
were within normal limits in 6 (20.0%) patients. 
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15. VISUAL ACUITY AT PRESENTATION, 2 WEEKS AND 3 
MONTHS AFTER TREATMENT IN Log MAR SCALE: 
PERIOD 
NO. 
OF 
EYES 
MEAN S.D 
S.E 
OF 
MEAN 
MINIMUM MAXIMUM 
0 Month 37 0.80 0.52 0.08 0.0 1.77 
2 Weeks 37 0.38 0.29 0.05 0.0 1.00 
3 Months 37 0.14 0.18 0.02 0.0 0.60 
 
Table 15: Visual acuity at presentation, 2 weeks and 3 months 
following treatment 
  
Chart 15: Line diagram showing improvement in visual acuity 
presented in  Log MAR scale 
 
 In this study, the mean best corrected visual acuity in patients 
was 0.80 in Log MAR scale at presentation which improved to 0.38 at 2 
weeks following treatment and to 0.14 following 3 months of treatment. 
Rapid improvement in vision occurred in the first two weeks following 
treatment. The number of eyes involved were 37 in 30 patients. 7 
patients had bilateral involvement. 
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16. IMPROVEMENT IN VISION AT 2 WEEKS FOLLOWING 
TREATMENT: 
BCVA 
95% Confidence 
Interval of the 
Difference 
t df p VALUE 
LOWER UPPER    
Presentation- 
2 weeks treatment 0.30 0.54 7.47 36 0.000 
 
Table 16: Improvement in vision after 2 weeks of treatment 
 In this study, on comparing the means of BCVA at presentation 
and after 2 weeks of treatment showed statistically significant 
improvement (p<0.001). 
 
17. IMPROVEMENT IN VISION AT 3 MONTHS FOLLOWING 
TREATMENT: 
BCVA 
95% Confidence 
Interval of the 
Difference 
t df p VALUE 
Lower Upper    
Presentation- 
3 months 
treatment 
0.50 0.83 8.07 36 0.000 
 
Table 17: Improvement in vision after 3 months of treatment 
In this study, on comparing the means of BCVA before and after 
3 months of treatment showed statistically significant improvement 
(p<0.001). 
77 
 
DISCUSSION 
Tuberculous uveitis is the most common cause of infectious 
uveitis in immunocompetent patients and third most common cause in 
immunocompromised patients following Cytomegalovirus and 
Toxoplasmosis retinitis. Owing to difficulty in diagnostic techniques to 
arrive at a ‘definite’ diagnosis because of limited samples of ocular 
fluids and highly controversial biopsy, the true prevalence of 
tuberculous uveitis is often masked. This study conducted at a highly 
endemic country highlights the importance of recognizing the myriad 
presentation of tuberculous uveitis among the population and to make a 
clinically ‘presumed’ tuberculous uveitis diagnosis taking the cues from 
the patient and the physician’s experience. 
In this study,the common age group presenting with tuberculous 
uveitis were found to be between 35-44 years with a mean age of 38.6 
years which is similar to the study conducted by Bansal R et. al.[44], 
2008. which showed the mean age to be 34.79 ± 10.74 years. 
In this study, tuberculous uveitis was more common among 
males (63%) whereas in Ang M et. al.[45] 2012 showed an inclination 
towards the female population and Sanghavi et al[46] 2011 study also 
showed a slight female (59%) preponderance in non-endemic areas. 
 In this study, risk of tuberculous uveitis was more among 
immunocompetent patients with history of exposure (66.67%). This 
suggest a hypersensitive reaction or re-activation of LTBI.  
78 
 
In this study, 43.4% of patients had involvement of the left eye 
and 22.3% of patients had a bilateral involvement. 
 In this study, defection vision was present in 86.7% of the 
patients and is the commonest presenting symptom. The causes for 
defective vision are lesion in macula, vitritis, serous detachment at 
macula, macular edema and anterior segment reaction. Floaters were 
present in 33.3% and redness, pain and photophobia in 6.7%. 
 In this study, 20% had a history of recurrence of the disease prior 
to anti-tuberculous therapy and a study by D. Varma et. al.[47]. showed 
chronic and recurrent tubercular uveitis responding well to ATT. 
In this study posterior uveitis (76.7%) was the most common 
presentation in tubercular uveitis followed by intermediate uveitis 
(16.7%) which is similar to Gupta et. al.[48] study.Among posterior 
uveitis choroidal tuberculoma and choroiditis are together present 
in46.7%. In this study, all patients with choroidal tubercles had 
disseminated tuberculosis suggesting a hematogenous spread infecting 
the choroid. Illingworth et. al. showed 60% of miliary tuberculosis 
patients presented with choroidal tubercles helping in the diagnosis even 
before radiological diagnosis. 
In this study, 7 (23.33%)patients had bilateral involvement of 
which 4 (13.33%) patients had intermediate uveitis and 3(10%) patients 
had posterior uveitis. Among the 3 posterior uveitis 2 patients had 
serpiginous-like choroiditis and 1 patient presented with choroiditis. 
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In this study, 13 (43.3%) patients had BCVA at presentation of 
<6/60 in which 11 patients had posterior uveitis. 11 (36.7%) patients had 
BCVA between 6/18-6/60 of which 6 patients had posterior uveitis and 
4 patients intermediate uveitis. 3 (10%) patients had BCVA 6/9-12 and 
3(10%) patients had no defective vision. 
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CONCLUSION 
Tuberculous etiology as a cause of uveitis surfaces the mind 
when patients present with clinical signs such as granulomatous uveitis, 
broad synechiae, tuberculoma, tubercle but what if a patient present with 
chronic and relapsing intermediate, non-granulomatous anterior uveitis 
or retinal vasculitis. India being an endemic country and control of 
tuberculosis being far from reach and with emergence of MDR-TB and 
with unwavering incidence due to poor socio-economic conditions, 
overcrowding and illiteracy a suspicion of tuberculous etiology is 
always maintained. 
In this study, exposure history and past history of tuberculosis, 
Mantoux positivity, indolent recurrent course and the variable 
presentations are considered in arriving at a presumed diagnosis of 
tuberculous uveitis.Choroiditis and choroidal tuberculoma were the most 
common presentation followed by intermediate uveitis.  
Patients responded to treatment with anti-tuberculosis therapy 
and corticosteroids and there were no recurrences in the follow-up 
period.  
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PROFORMA 
NAME: 
AGE/ SEX: 
ADDRESS: 
O.P NO: 
CHIEF COMPLAINTS: 
HISTORY OF PRESENTING ILLNESS: 
H/O defective vision, floaters 
H/O pain, redness, photophobia  
H/O contact with tuberculosis patients 
PAST HOSTORY: 
H/O similar episodes in the past 
H/O diabetes, hypertension  
H/O pulmonary or extra pulmonary tuberculosis  
H/O previous Anti Tuberculosis Therapy 
H/O previous ocular surgery. 
FAMILYHISTORY: 
H/O diabetes, hypertension  
 H/O tuberculosis in family members  
TREATMENT HISTORY: 
Any medical/surgical treatment for the current illness 
 
  
x 
 
GENERAL EXAMINATION 
             Built 
             Nourishment 
             Anaemia/jaundice/cyanosis/clubbing/lymphadenopathy 
             Vitals-pulse, temperature, blood pressure, respiratory rate 
OCULAR EXAMINATION 
RIGHT EYE EXAMINATION LEFT EYE 
 Visual acuity  
 Eyelids  
 Extraocular movements 
 
 Conjunctiva  
 Cornea  
 Anterior chamber  
 Iris  
 Pupil  
 Lens  
 
Fundus examination 
 
 
 Intraocular pressure  
 
xi 
 
OTHER SYSTEMS: 
Respiratory system, Cardiovascular System and Abdominal 
examination 
OTHER CONSULTATION: 
General Physician and Chest Physician Opinion  
PROVISIONAL DIAGNOSIS: 
INVESTIGATIONS: 
Complete Blood Count with hemogram, Erythrocyte 
Sedimentation Rate, Blood Sugar, Blood Pressure, VDRL, HIV ELISA, 
Toxocara ELISA, TORCH Serology tests, Tuberculin Skin Tests, Chest 
Radiograph. 
Fundus Fluorescein Angiography. Optical Coherence Tomography, 
Ultrasound Biomicroscopy. 
FINAL DIAGNOSIS: 
TREATMENT: 
FOLLOWUP PERIOD: 
2 weeks 
1 month 
3 months 
And when needed. 
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KEY TO MASTER CHART 
S.No – Serial number 
Sex 
 M -Male 
 F – Female 
Eye 
 RE – Right eye 
 LE – Left Eye 
 BE – Both eye 
DV – Defective vision 
Y -Yes 
N – No 
R /P / Ph – Redness/ Pain/ Photophobia 
CHx – Chest X-ray 
Pul TB – Pulmonary Tuberculosis 
ExtraPul Tb – Extra-Pulmonary Tuberculosis 
Rec Hx – Recurrence history 
IOP – Intraocular pressure 
Cornea 
 C – Clear 
 KPs – Keratic Precipitates 
AC – Anterior Chamber 
Q – Quiet 
xiii 
 
C – Cells 
F – Flare 
Pupil 
 RTL – Reacting to Light 
 PS – Posterior synechiae 
 SRTL – Sluggishly reacting to light 
Lens 
 NS – Nuclear sclerosis 
 IPs – Iris pigments 
TST – Tuberculin Skin Test 
CXR – Chest X-ray 
 N – normal 
Diagnosis 
 SLC – Serpiginous-like choroiditis 
Management 
 ATT – Anti tuberculosis therapy 
 S(o) – Oral steroids 
 S (t) – Topical steroids 
 S (p) – Periocular steroids 
 C – Cycloplegics 
BCVA – Best Corrected Visual Acuity 
 2wks – 2weeks, 1mo – I month, 3 mo – 3 months. 
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MASTER CHART 
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